Tabacco G, et al. - In this prospective, open-label trial involving 20 hypoparathyroid patients, researchers assessed the effects of 8 years of rhPTH(1-84) therapy on quality of life (QoL) and factors correlated with long term benefit. Main outcomes and measures included RAND 36-Item Short Form (SF-36) Health Survey. Investigators found that mental component summary (MCS) and physical component summary (PCS) scores improved more in patients with reduced calcium supplementation than those whose supplementation did not decline to the same degree. In hypoparathyroidism, rhPTH(1-84) improves long-term well-being. Findings revealed that the most prominent improvements are those with baseline impaired SF-36 and those whose requirements for conventional therapy dropped substantially.